1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2. A High-Throughput Process for Valsartan
3. Multiple routes to compound 2 have been reported in
the literature, most of them providing compound 2 in
enantioselectivities of > 99:1 e.r. and diastereoselectivities
of > 99:1 d.r. in favor of the desired stereoisomer.
For key examples, seeaHook, D.; Ruch, T.; Riss, B.; Wietfeld, B.; Sedelmeier, G.; Napp, M.; Bänziger, M.; Hawker, S.; Ciszewski, L.; Waykole, L. M. Process for Preparing 5-Biphenyl-4-Amino-2-Methyl Pentanoic Acid. PCT Patent Appl. WO/2008/083967, October 01, 2008.
4. bHook, D.; Wietfeld, B.; Lotz, M. Process for Preparing Biaryl Substituted 4-Amino-Butyric Acid or Derivatives Thereof and Their Use in the Production of NEP Inhibitors. PCT Patent Appl. WO/2008/031567, September 11, 2007.
5. cZhu, G.; Ye, W.; Zheng, H.; Qian, L.; Wei, J.; Yang, L.; Li, Y.; Luo, L. New Process. PCT Patent Appl. WO/2014/032627, September 02, 2013.